BTIG analyst Mark Massaro maintains $GeneDx Holdings (WGS.US)$ with a buy rating, and adjusts the target price from $45 to $95.
According to TipRanks data, the analyst has a success rate of 29.1% and a total average return of -10.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GeneDx Holdings (WGS.US)$'s main analysts recently are as follows:
GeneDx's considerable Q3 revenue surpassing expectations reflects the company's robust growth and effective execution. Although the company's valuation suggests a significant premium, this has been acknowledged. Moreover, the updated revenue forecasts for 2024-2026 indicate heightened expectations. The company's leadership is recognized for achieving one of the most remarkable and swift turnarounds in the sector.
GeneDx's recent Q3 report was characterized as 'another strong' performance, with an 18% revenue beat and an upward revision of the fiscal year revenue guidance. Significantly, the company achieved its profitability targets much sooner than anticipated.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BTIG分析師Mark Massaro維持$GeneDx Holdings (WGS.US)$買入評級，並將目標價從45美元上調至95美元。
根據TipRanks數據顯示，該分析師近一年總勝率為29.1%，總平均回報率為-10.4%。
此外，綜合報道，$GeneDx Holdings (WGS.US)$近期主要分析師觀點如下：
GenedX第三季度可觀的收入超出預期，這反映了該公司的強勁增長和有效的執行。儘管該公司的估值表明溢價幅度很大，但這一點已得到承認。此外，最新的2024-2026年收入預測表明，預期有所提高。該公司的領導地位因實現該行業最引人注目和最迅速的轉型之一而受到認可。
GenedX最近的第三季度報告被描述爲 「又一次強勁」 的表現，收入超過18％，財年收入指引向上修正。值得注意的是，該公司實現盈利目標的速度比預期的要早得多。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
